Eupraxia Pharmaceuticals (TSE:EPR) Stock Rating Raised to Strong-Buy at Wedbush

Wedbush upgraded shares of Eupraxia Pharmaceuticals (TSE:EPR – Free Report) to a strong-buy rating in a research report report published on Thursday morning,Zacks reports.

Eupraxia Pharmaceuticals Stock Performance

Get Eupraxia Pharmaceuticals alerts:

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biotechnology company developing locally acting therapies designed to improve the delivery, duration and tolerability of established medicines. The company’s platform, DiffuSphere, uses biodegradable polymeric microspheres to provide controlled and sustained drug release at targeted sites in the body.

Eupraxia’s lead programs include EP-104IAR, an extended-release intra-articular formulation intended to provide longer-lasting relief for people with knee osteoarthritis, and EP-104GI, an orally administered formulation being developed for gastrointestinal diseases, including eosinophilic esophagitis.

Featured Stories

• Five stocks we like better than Eupraxia Pharmaceuticals
• Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
• Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
• Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
• Oil May Be Stronger Than It Looks—And Diamondback Is on Sale

Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.